Mirum presents new Phase III data on Livmarli

US biotech Mirum Pharmaceuticals (Nasdaq: MIRM) saw its shares rise 3% to $23.69 yesterday, when it presented new data from Livmarli (maralixibat) oral solution studies at The Liver Meeting of the American Association for the Study of Liver Diseases.

Following previously reported positive top-line results from the Phase III MARCH study in progressive familial intrahepatic cholestasis (PFIC)) showing statistically-significant improvement in pruritus and serum bile acid in PFIC2 and all PFIC, additional data presented showed that these improvements were also statistically-significant when looking at the FIC1, MDR3, TJP2, and MYO5B patients alone, persisting over the 26 weeks of study.

Last year, the US Food and Drug Administration has approved Livmarli oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. It is also awaiting European Commission clearance in this indication, following a positive recommendation the European Medicines Agency’s advisory committee last month.